tbuckley/cabot-search huggingface dataset:
Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.
Authors: Libor Havel, Milada Zemanova, Milos Pesek, Vitezslav Kolek, Radek Spisek, Jirina Bartunkova, Ladislav Pecen, Inna Krasnopolskaya, Markéta Cernovská
Journal: Journal of Clinical Oncology (2018)

9051 Background: Immunotherapy for induction of tumor cell specific immune responses destroying tumor cells, has emerged as a promising treatment modality in lung cancer (LuCa). Autologous DCVAC can present tumor antigens to elicit a durable immune response. We hypothesized that adding DCVAC to the standard of care chemotherapy (ct) could prolong progression-free survival (PFS) and overall survival (OS). Methods: This study evaluated the efficacy and safety of DCVAC/LuCa (active cellular immunotherapy based on dendritic cells) concomitantly added to ct (carboplatin/paclitaxel) - Arm A (A) vs DCVAC/LuCa + immune modulators (IFN-α and hydroxychloroquine) - Arm B (B) vs ct - Arm C (C) in NSCLC patients (pts). Randomization 1:1:1; pts in A and B received up to 15 doses of DCVAC, ct was given 4-6 cycles in A and C. Stage IV NSCLC was confirmed histologically or cytologically, ECOG 0-1 pts were eligible. Stratification was done by histology subtype and smoking history. Primary efficacy analysis compared A vs C only as enrollment to B was closed early based on Sponsor’s assessment of further clinical development potential, there were no safety concerns or signals. Results: 112 pts at 12 sites were randomized (A/45 B/29 C/38). Patients characteristics were comparable across the study groups with the exception of gender (m/f, %: 50/50 (A) and 26/74 (C) and smoking history (75 % of smokers in A, 97 % in C). Median follow up time was 14.1 months, range 0.032-29,765. Median OS was 15.5 months in A compared to 11.8 months in C, hazard ratio (HR) 0.56, p-value 0.05, 95% CI, data maturity 65%. Median PFS was 6.73 in A and 5.65 months in C HR 0.64, p-value 0.05, 95% CI, data maturity 81%. Overall response rate was 45% in A vs 22.9% in C. Most TEAEs were related to ct (anemia [37%-A, 32%-C], neutropenia [48% in A, 21%-C], thrombocytopenia [28% in A, 27% in C]). There were no grade ≥ 3 TEAEs solely related to DCVAC. Most common leukapheresis-related AEs were haematoma and hypotension. Conclusions: Addition of DCVAC-based immunotherapy to the standard of care chemotherapy significantly improved OS in stage IV NSCLC. Clinical trial information: EudraCT 2014-003084-37.
A Text=Book of Pathology.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Value of prednisone in combination chemotherapy of stage IV Hodgkin's disease. Report from the British National Lymphoma Investigation.
Authors: G Edelstyn, J Robertson); Queen, G Newsholme, Cambridge Addenbrooke's, Elizabeth Kingsley- Pillers, F Hayhoe, ' Kok, Canterbury Kent, Shirley Drake, M Rake, D Lillicrap, H Sterndale, D Taylor, Cardiff Velindre, I Howell, Evans Cheltenham, D Mahy, Warwickshire Coventry, T Backhouse, R Das, A Moon, T Cookridge, J Worthy, A Stone, Royal Clatterbridge, Alder Infirmary, W Hey Children's, Liverpool, M Dawson, R Garrett, J Ryall, J Brock, ( London, B Hope-Stone, Middlesex Mantell, A Jelliffe, N Bleehen, A Strickland
Journal: BMJ (1975)

A combination of mustine, vincristine (Oncovin), procarbazine, and prednisione (MOPP) and the same combination without prednisone (MOP) were compared in the treatment of stage IV Hodgkin's disease in a prospective randomized trial. The complete remission rates were 80% with MOPP and 44% with MOP; the difference was highly significant. Prednisone seems to be an important component of the MOPP combination in the management of stage IV Hodgkin's disease.
Passive transfer of antibodies to human T-cell lymphotropic virus type III in patients receiving high-dose intravenous immunoglobulin
Authors: W. B. White
Journal: JAMA (1986)

<h3>To the Editor.—</h3> Immune serum globulins derived from pooled plasma are being scrutinized as a possible source of viral infection and a cause of seroconversion to the viral antibodies.<sup>1,2</sup>Recently, there has been evidence that antibody to human T-cell lymphotropic virus type III (anti-HTLV-III) is present in anti-hepatitis B immunoglobulin and may inducea transient seroconversion.<sup>2</sup>Fortunately, there is no evidence that hepatitis B vaccines transmit HTLV-III infection or are associated with the development of the acquired immunodeficiency syndrome.<sup>2,3</sup>We recently evaluated several immunoglobulin preparations for the presence of anti-HTLV-III and studied whether hypogammaglobulinemic patients who had been receiving high-dose intravenous immunoglobulins developed positive serological test findings for anti-HTLV-III. Four of five immunoglobulin preparations were positive for anti-HTLV-III by enzyme immunoassay; however, only two preparations were positive by Western blot analysis (Table). Eleven patients with common variable hypogammaglobulinemia who had received intravenous immunoglobulin therapy for more than two years were studied. None of these
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer
Authors: Beatrice Rondinelli, Dalia Rosano, Elena Antonini, Michela Frenquelli, Laura Montanini, DaChuan Huang, Simona Segalla, Kosuke Yoshihara, Samir B. Amin, Dejan Lazarevic, Bin Tean The, Roel G.W. Verhaak, P. Andrew Futreal, Luciano Di Croce, Lynda Chin, Davide Cittaro, Giovanni Tonon
Journal: Journal of Clinical Investigation (2016)

in Figures 1B, 3C, and4C.After an extensive internal review,
The relationship of tampon characteristics to menstrual toxic shock syndrome
Authors: S. F. Berkley
Journal: JAMA (1987)

The pathogenic basis for the association of tampons with toxic shock syndrome (TSS) has not been explained adequately. Absorbency and chemical composition of tampons are related, and no prior study has had a sufficient number of cases to evaluate these independently as risk factors for disease. We compared national TSS passive surveillance data on the 285 tampon-associated menstrual cases of TSS reported from 1983 to 1984 with data on age- and year-matched controls from national surveys of tampon usage. Users of all brands of tampons had elevated risks when compared with non—tampon users (odds ratio, 32.8; 95% confidence interval, 15.5,69.6). Regardless of the chemical composition of the tampon, increasing absorbency increased the odds ratio for TSS. Chemical composition also influenced odds ratios. Polyacrylate-containing tampons had odds ratios that were elevated but, once controlled for absorbency, that were lower than the odds ratios for cotton, rayon, and cotton/rayon tampons. The strong association of absorbency with risk of illness would suggest that as a public health measure the use of a low-absorbency tampon is likely to reduce the risk of TSS in the user. (<i>JAMA</i>1987;258:917-920)
Carl Thiersch (1822-1895) Leipzig Surgeon
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction to: Platelet Protein Disulfide Isomerase Promotes Glycoprotein Ibα-Mediated Platelet-Neutrophil Interactions Under Thromboinflammatory Conditions
Journal: Circulation (2019)

There were also errors in the representative histograms shown in Figure 3, panels 3H and 3K, which have now been replaced.In the results section, the following sentence appeared: "As analyzed by flow cytometry with different monoclonal anti-GPIbα antibodies, MM2/174 recognizing the elastase-resistant part of GPIbα 36 equally detected WT and mutant GPIbα on CHO cells with two populations (Figure 3H-I)."And has now been updated to:As analyzed by flow cytometry with different monoclonal anti-GPIbα antibodies, MM2/174 recognizing the elastase-resistant part of GPIbα 36 equally detected WT and mutant GPIbα on CHO cells (Figure 3H-I).Additionally, the following sentences were added to the discussion section: "Furthermore, it is noticeable that although Cys209Ser mutation in the GPIbα gene has been associated with Bernard-Soulier syndrome 45 and Cys209Ser mutant GPIbα was not transiently expressed in CHO cells already expressing GPIbβ and GPIX, 46 under our conditions the mutant protein along with GPIbβ and GPIX was expressed on the surface of CHO cells as detectable by anti-GPIbα antibodies or vWF binding.The reason for these apparent differences between the studies is not known.
Methyldopa Hyperpyrexia
Authors: William A. Parker
Journal: JAMA (1974)

<h3>To the Editor.—</h3> Our Clinical Pharmacy Service has recently been consulted regarding two cases of fever of unknown origin, ultimately determined to be due to methyldopa (Aldomet). Although not a rare occurrence, this adverse drug reaction can present a confusing clinical picture. As with most drug reactions, a good medication and clinical history are essential to diagnosis. <h3>Report of a Case.—</h3> A 66-year-old white man suffered a blackout and absence spell, with a positive history of seizure disorder, hypertension, hyperlipidemia, and sulfonamide rash. Two weeks earlier, he had abruptly stopped taking reserpine, potassium chloride, diphenylhydantoin, and a triamterene-hydrochlorothiazide combination. Laboratory findings were as follows: Blood glucose, 150 mg/100 ml; total serum bilirubin, 1.5 mg/100 ml; total serum protein, 5.8 gm/100 ml with albumin, 3.4 gm/100 ml; and lactic dehydrogenase, 120. The blood pressure was 190/100 mm Hg. Diphenylhydantoin and methyldopa, 250 mg twice daily, were given. On the 11th day,
Eleventh Annual Report of the State Board of Health of Illinois,
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
USPSTF Calls for More BRCA Screening
Journal: Cancer Discovery (2019)

Abstract A recent U.S. Preventive Services Task Force statement reiterates the importance of screening women for BRCA1/2 mutations and recommends that more women undergo risk-assessment screening, including those with a personal history of certain cancers and those with certain ancestries. Experts consider the recommendations a positive, if incremental, step that will likely have the biggest impact on community practices.
Flood Warning
Authors: Joan Stephenson
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.
Authors: Ramy Saleh, Philippe L. Bedard, Paul Nguyen, Eoghan Ruadh Malone, Celeste Yu, Eitan Amir, Craig Earle, Bishal Gyawali, Aaron Richard Hansen, Nicole Mittmann, Yingwei Peng, Trevor J Pugh, Albiruni Ryan Abdul Razak, Peter Sabatini, Anna Spreafico, Tracy Stockley, Jonathon Torchia, Christine Williams, Lillian L. Siu, Timothy P Hanna
Journal: Journal of Clinical Oncology (2020)

e19303 Background: There is limited real-world evidence of impact of large clinical panel sequencing on treatment-matching for patients with advanced solid tumors. The province of Ontario has a single payer, publicly funded health care system. We linked genomic testing results from a prospective province-wide trial, OCTANE (Ontario-Wide Cancer TArgeted Nucleic Acid Evaluation), to administrative data to determine the feasibility of this approach for evaluating survival and the impact of sequencing on treatment matching. Methods: We linked all Ontario patients from Princess Margaret (PM) with panel testing results (tumor-only 555-gene panel) to province-wide administrative data on treatments and outcomes. Patients were recruited from August 2016 to August 2018. Only clinically actionable variants based upon OncoKB annotation (Level 1 and 2) were assessed for genotype-informed treatment matching. Results: All 888 eligible patients were successfully linked to administrative data. Mean age was 58 (±13) years, 635 (71.5%) were female. Most common disease sites were ovary (26.4%), uterus (14.0%), colorectal (11.8%) and breast (9.5%). Administrative data vital status was more complete than trial collected data with 262 of 476 deaths only recorded in administrative data. Median survival was 1.70 years (95% confidence interval 1.50-1.91). 247 (27.8%) had actionable mutations, most commonly PIK3CA (54.7%), BRCA1 (15.8%), BRCA2 (15.0%) and BRAF (8.9%). 37 (15.0%) and 42 (17.0%) patients with actionable mutations received targeted therapy within 6 and 12 months of test report date, respectively. Conclusions: This is the first known feasibility study of linked administrative data to measure outcomes of large clinical panel sequencing for patients with advanced solid tumors. Vital status was more complete with administrative data compared to trial-collected data, and treatment data was successfully linked. About one in twenty-one enrolled patients received genome-informed treatments within 12 months, or about one in six of all patients with actionable mutations. This may be due to short interval follow up, trial and drug access, successful standard of care treatments, early patient deterioration or limited alterations covered by the panel, among other causes.
Urology.
Authors: Thomas A. Stamey
Journal: JAMA (1963)

The first edition of Campbell's<i>Urology</i>was published in 1954 and comprised 2,356 pages written by 51 contributing authors. This second edition is 530 pages longer and has 64 authors. There are several other significant differences. The important section on anatomy and physiology is strengthened by replacing the limited pyelographic approach to the physiology of the renal pelvis and ureter, present in the first edition, with the more exact electrical and manometric data of Fredrik Kiil, Professor of Medicine at the University of Oslo. The precise studies relating to the neurophysiology of micturition are placed in the section on physiology rather than in the chapter on neuromuscular disease, a change which again strengthens the introductory section. R. F. Pitt's excellent chapter on renal function in the first edition is replaced by J. P. Merrill's equally fine section on normal and abnormal renal function, together with the treatment of renal failure.
Roslinne jittya ta nervova sistema.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Final Programme
Authors: M Ertas Gokhan, P Ertan, P Karaoz, M Ahmet, C Van Der, Pouw Kraan, S Schirmer, J Fledderus, P Moerland, T Leyen, J Piek, N Royen, A Horrevoets, F Fleissner, V Jazbutyte, J Fiedler, P Galuppo, M Mayr, G Ertl, J Bauersachs, T Thum, E Scoditti, M Massaro, M Carluccio, A Distante, C Storelli, R De Caterina, S Suvorava, M Kumpf, M Floeren, G Oppermann, Du Kojda, M Chittari Macharotu, P Mc Ternan, N Bawazeer, K Lois, P O'hare, S Kumar, A Ceriello, C Leo, J Ziogas, J Favaloro, O Woodman, W Li, Y Kwan, G Leung, N Barth, A Loot, I Fleming
Journal: Cardiovascular Research (2010)

Your poster must be set up between 08:00 and 08:30, and be on display until 17:30.You must remove it between 17:30 and 18:00.You or one of your co-authors are advised to be present throughout the coffee
TREATMENT OF COLLES' FRACTURE.
Authors: EDWARD A. TRACY
Journal: JAMA (1897)

In 1814, Colles of Dublin published his observations on the fracture which today deservedly bears his name. Previous to that time this injury practically masqueraded under the description of backward dislocation of the wrist or forward dislocation of the lower end of the radius (!), for such dislocations were considered common by the masters from Hippocrates down. The nearness of the fracture to the wrist joint, the peculiarity of its anatomic surroundings, the absence of the characteristic sign of fracture unless specially sought for, and finally the teaching of the masters, all served to hinder the recognition of the actual occurrence in this injury, fracture. Therefore, to Colles will ever be due our appreciation and gratitude for the correct diagnosis of this injury, for correct treatment in surgery is dependent upon right diagnosis to even a greater degree than in medicine. In this paper the writer will quote the views of
Abstract 2787: Elevated Circulating Levels Of Platelet-derived Microparticles Are Associated With The Thrombus Formation In The Left Atrial Appendage In Patients With Ischemic Stroke That Is Resistant To Anti-coagulant Therapies
Authors: Harutoshi Tamura, Osamu Hirono, Hidenobu Okuyama, Satoshi Nishiyama, Yasuchika Takeishi, Takamasa Kayama, Isao Kubota
Journal: Circulation (2007)

Introduction: It is well known that elevation of fibrinolytic markers reflects thrombus formation in the left atrial appendage (LAA) that is identified as a fibrin-rich thrombus. On the other hand, it is sometimes difficult to remove LAA thrombus by the treatment of anti-coagulants alone. Hypothesis: Circulating platelet activation is also responsible for the thrombus formation in the LAA in patients with cardioembolic stroke. Methods: In 98 consecutive patients with cerebral infarction (mean age, 71±12 years old), we performed trans-esophageal echocardiography within 7 days after the onset, and at the same time, measured circulating platelet-derived microparticles (PDMP, as a marker of platelet activation, &lt; 20 U/ml), and serum levels of D-dimer (DD, as a marker of fibrinolytic activity, normal level &lt; 1.0 μg/ml). Patients with LAA peak emptying flow velocity &lt; 20 cm/s were classified as having LAA dysfunction. Results: In patients without warfarin treatment, both PDMP and DD levels were significantly higher in LAA thrombus positive (n=12) than in negative group (n=70) (PDMP, 113.5±80.4 vs. 65.5±30.7 U/ml, P&lt;0.001; DD, 7.3±10.4 vs. 2.9±3.7 μg/ml, p &lt; 0.01). In patients with warfarin treatment (PT-INR 1.64±0.35), PDMP, but not DD levels, was markedly higher in LAA thrombus positive (n=6) than in negative group (n=10) (PDMP, 113.4±84.5 vs. 49.7±23.9 U/ml, P&lt;0.05; DD, 2.1±1.8 vs. 1.6±1.3 μg/ml, NS), because DD were effectively suppressed by the anti-coagulant therapy. Furthermore, in LAA thrombus negative patients, there were no significant differences in PDMP between cases with and without LAA dysfunction (LAA dysfunction, n=13, 70.2±26.5 vs. No dysfunction, n=67, 63.3±31.1 U/ml). Conclusions : PDMP plays an important role in the LAA thrombus formation that is resistant to anti-coagulant treatment, and may be a useful predictor for the cardioembolic stroke occurrence.